U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C46H58ClN5O8
Molecular Weight 844.434
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROGLUMETACIN

SMILES

CCCN(CCC)C(=O)C(CCC(=O)OCCCN1CCN(CCOC(=O)CC2=C(C)N(C(=O)C3=CC=C(Cl)C=C3)C4=C2C=C(OC)C=C4)CC1)NC(=O)C5=CC=CC=C5

InChI

InChIKey=PTXGHCGBYMQQIG-UHFFFAOYSA-N
InChI=1S/C46H58ClN5O8/c1-5-21-51(22-6-2)46(57)40(48-44(55)34-11-8-7-9-12-34)18-20-42(53)59-29-10-23-49-24-26-50(27-25-49)28-30-60-43(54)32-38-33(3)52(41-19-17-37(58-4)31-39(38)41)45(56)35-13-15-36(47)16-14-35/h7-9,11-17,19,31,40H,5-6,10,18,20-30,32H2,1-4H3,(H,48,55)

HIDE SMILES / InChI

Molecular Formula C46H58ClN5O8
Molecular Weight 844.434
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Proglumetacin (usually as the maleate salt, trade names Afloxan, Protaxon and Proxil) is a non-steroidal anti-inflammatory drug. Proglumetacin is indicated for the pain and inflammation associated with musculoskeletal and joint disorders. The action of proglumetacin maleate is qualitatively the same as that of indomethacin in vivo; that is, it inhibits cyclo-oxygenase in inflammatory sites.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Afloxan

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Oral Pain and inflammation associated with musculoskeletal and joint disorders Adult: Up to 600 mg/day in divided doses.
Route of Administration: Oral
In Vitro Use Guide
PGM (IC50 = 1.5 uM) strongly inhibited 5-HETE formation by the cytosol of guinea pig polymorphonuclear leukocytes.
Substance Class Chemical
Record UNII
FV919079LU
Record Status Validated (UNII)
Record Version